-
公开(公告)号:US20090018331A1
公开(公告)日:2009-01-15
申请号:US12199982
申请日:2008-08-28
申请人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Kazunobu Kira , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki
发明人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Kazunobu Kira , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki
IPC分类号: C07D498/14 , C07D473/04 , C07D487/04
CPC分类号: C07D473/30 , C07D471/04 , C07D473/04 , C07D473/06 , C07D473/18 , C07D473/36 , C07D473/40 , C07D487/04 , C07D491/14
摘要: The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
摘要翻译: 本发明涉及由下式表示的化合物或其盐或水合物,其中,T1表示在环中含有一个或两个氮原子的4至12元杂环基,其为单环或双环结构,其可以是 具有一个或多个取代基; X表示可以具有一个或多个取代基的C 1-6烷基; Z 1和Z 2各自独立地表示氮原子或由式-CR 2表示的基团; R1和R2独立地表示氢原子,可以具有一个或多个取代基的C 1-6烷基或可以具有一个或多个取代基的C 1-6烷氧基等。 这些是表现出优异的DPPIV抑制活性的新型化合物。
-
公开(公告)号:US20080132507A1
公开(公告)日:2008-06-05
申请号:US11665385
申请日:2005-10-13
申请人: Richard Clark , Shinsuke Hirota , Hiroshi Azuma , Kazunobu Kira , Nobuhisa Watanabe , Tadashi Nagakura , Tatsuo Horizoe
发明人: Richard Clark , Shinsuke Hirota , Hiroshi Azuma , Kazunobu Kira , Nobuhisa Watanabe , Tadashi Nagakura , Tatsuo Horizoe
IPC分类号: A61K31/5375 , C07D213/02 , C07D239/24 , C07D333/02 , C07D307/02 , C07D215/00 , C07D295/00 , C07D249/04 , C07D241/10 , A61P9/10 , A61P11/00 , A61K31/4965 , A61K31/50 , A61K31/4192 , C07C63/00 , C07C57/00 , A61K31/19 , A61K31/44 , A61K31/505 , A61K31/381 , A61K31/47
CPC分类号: C07D209/48 , C07C257/18 , C07C311/49 , C07C317/14 , C07C317/44 , C07C337/06 , C07D209/08 , C07D213/30 , C07D213/54 , C07D213/71 , C07D213/77 , C07D213/80 , C07D213/82 , C07D213/86 , C07D213/87 , C07D213/89 , C07D215/38 , C07D233/90 , C07D237/20 , C07D239/28 , C07D239/42 , C07D249/18 , C07D257/04 , C07D295/32 , C07D307/68 , C07D333/24 , C07D471/04
摘要: A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc., R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc., Z1, Z2 and Z3 each independently represent hydrogen, etc., Z4 represents hydrogen, etc. and X represents a single bond or —CO—, etc.
摘要翻译: 由下列通式(1)表示的化合物或其盐或其水合物是安全的,同时具有合适的物理化学稳定性,并且可用作与血栓形成相关的疾病的治疗或预防剂。 其中R 1a,R 1b,R 1c和R 1d各自独立地表示氢等, O 2表示任选取代的苯基等,R 3表示任选取代的C 6-10芳基等,Z 1,Z 2, Z 3和Z 3各自独立地表示氢等,Z 4表示氢等,X表示单键或-CO-等。
-
公开(公告)号:US07238720B2
公开(公告)日:2007-07-03
申请号:US10766388
申请日:2004-01-27
申请人: Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki , Seiji Yoshikawa , Toshimi Okada , Hironori Ikuta , Mika Koyanagi
发明人: Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki , Seiji Yoshikawa , Toshimi Okada , Hironori Ikuta , Mika Koyanagi
IPC分类号: A61K31/4196 , A61K31/416 , C07D43/02
CPC分类号: C07D451/02 , C07D249/12 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D471/04
摘要: The present invention relates to use of 1-carbamoylazole derivatives as medicaments and pharmaceutical compositions containing 1-carbamoylazole derivatives as the active ingredient, based on their DPPIV inhibiting effects. The present invention provides a dipeptidyl peptidase IV inhibiting agent comprising a compound represented by the general formula (I):
摘要翻译: 本发明涉及1-氨基甲酰唑衍生物作为药物的用途,以及含有1-氨基甲酰唑衍生物作为活性成分的药物组合物,基于其DPPIV抑制作用。 本发明提供了包含通式(I)表示的化合物的二肽基肽酶IV抑制剂:
-
公开(公告)号:US07816522B2
公开(公告)日:2010-10-19
申请号:US11723893
申请日:2007-03-22
申请人: Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
发明人: Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
IPC分类号: A61K31/41 , A61K31/415 , C07D233/00 , C07D249/00
CPC分类号: C07D249/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D413/14 , C07D417/04
摘要: A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen]
摘要翻译: 由以下通式(1)表示的化合物,其盐或其前体的水合物是可用于治疗和/或预防与血栓形成有关的疾病的新型化合物,其具有合适的理化稳定性更安全。 [其中R1a,R1b,R1c和R1d各自独立地表示氢等; R2代表任选取代的苯基等; R3代表任选取代的C6-10芳基等; 并且Z 1和Z 2各自独立地表示氢]
-
公开(公告)号:US07807690B2
公开(公告)日:2010-10-05
申请号:US12234116
申请日:2008-09-19
申请人: Richard Clark , Atsushi Takemura , Nobuhisa Watanabe , Osamu Asano , Tadashi Nagakura , Kimiyo Tabata
发明人: Richard Clark , Atsushi Takemura , Nobuhisa Watanabe , Osamu Asano , Tadashi Nagakura , Kimiyo Tabata
IPC分类号: A61K31/506 , A61K31/4439 , A61K31/427 , A61K31/422 , A61K31/4196 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D249/12
CPC分类号: C07D417/14 , C07D209/44 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要: A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.].
摘要翻译: 由以下通式(1)表示的化合物或其盐具有丝氨酸蛋白酶抑制活性,对凝血因子VIIa特别优异的抑制活性。 该化合物或其盐可用作与血栓形成相关的疾病的治疗和/或预防剂。 [其中R1表示氢,R2表示任选取代的苯基等,R 3表示任选取代的C 6-10芳基等]。
-
公开(公告)号:US20100240654A1
公开(公告)日:2010-09-23
申请号:US12791571
申请日:2010-06-01
申请人: Richard CLARK , Shinsuke HIROTA , Hiroshi AZUMA , Kazunobu KIRA , Nobuhisa WATANABE , Tadashi NAGAKURA , Tatsuo HORIZOE
发明人: Richard CLARK , Shinsuke HIROTA , Hiroshi AZUMA , Kazunobu KIRA , Nobuhisa WATANABE , Tadashi NAGAKURA , Tatsuo HORIZOE
IPC分类号: A61K31/5377 , C07C243/22 , A61K31/15 , C07D211/72 , A61K31/4402 , C07D215/38 , A61K31/47 , C07D239/32 , C07D295/28 , A61K31/5375 , C07D413/04 , A61P7/02 , A61P9/10 , A61P9/00 , A61P7/00
CPC分类号: C07D209/48 , C07C257/18 , C07C311/49 , C07C317/14 , C07C317/44 , C07C337/06 , C07D209/08 , C07D213/30 , C07D213/54 , C07D213/71 , C07D213/77 , C07D213/80 , C07D213/82 , C07D213/86 , C07D213/87 , C07D213/89 , C07D215/38 , C07D233/90 , C07D237/20 , C07D239/28 , C07D239/42 , C07D249/18 , C07D257/04 , C07D295/32 , C07D307/68 , C07D333/24 , C07D471/04
摘要: A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc., R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc., Z1, Z2 and Z3 each independently represent hydrogen, etc., Z4 represents hydrogen, etc. and X represents a single bond or —CO—, etc.
摘要翻译: 由下列通式(1)表示的化合物或其盐或其水合物是安全的,同时具有合适的物理化学稳定性,并且可用作与血栓形成相关的疾病的治疗或预防剂。 其中R1a,R1b,R1c和R1d各自独立地表示氢等,R2表示任选取代的苯基等,R 3表示任选取代的C 6-10芳基等,Z 1,Z 2和Z 3各自独立地表示氢等, Z4表示氢等,X表示单键或-CO-等。
-
公开(公告)号:US07772226B2
公开(公告)日:2010-08-10
申请号:US12199982
申请日:2008-08-28
申请人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Kazunobu Kira , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki
发明人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Kazunobu Kira , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki
IPC分类号: A61K31/437 , A61K31/496 , C07D487/04 , C07D471/04 , C07D473/06 , C07D473/18 , C07D473/22 , C07D473/30 , C07D473/40 , C07D498/14 , A61K31/5025 , A61K31/522
CPC分类号: C07D473/30 , C07D471/04 , C07D473/04 , C07D473/06 , C07D473/18 , C07D473/36 , C07D473/40 , C07D487/04 , C07D491/14
摘要: The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
摘要翻译: 本发明涉及由下式表示的化合物或其盐或水合物,其中,T1表示在环中含有一个或两个氮原子的4至12元杂环基,其为单环或双环结构,其可以是 具有一个或多个取代基; X表示可以具有一个或多个取代基的C 1-6烷基; Z 1和Z 2各自独立地表示氮原子或由式-CR 2表示的基团; R1和R2独立地表示氢原子,可以具有一个或多个取代基的C 1-6烷基或可以具有一个或多个取代基的C 1-6烷氧基等。 这些是表现出优异的DPPIV抑制活性的新型化合物。
-
公开(公告)号:US07074798B2
公开(公告)日:2006-07-11
申请号:US10374918
申请日:2003-02-24
申请人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki , Mika Aoki
发明人: Seiji Yoshikawa , Eita Emori , Fumiyoshi Matsuura , Richard Clark , Hironori Ikuta , Nobuyuki Yasuda , Tadashi Nagakura , Kazuto Yamazaki , Mika Aoki
IPC分类号: C07D473/06 , C07D473/08 , C07D473/04 , A61K31/522 , A61P3/10
CPC分类号: C07D473/06 , C07D473/08
摘要: The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect.The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, and R42 each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, which group may be substituted; and, R1 and R2 each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such, or salts or hydrates thereof.
摘要翻译: 本发明提供具有优异DPPIV抑制作用的新化合物。 化合物由下式表示:其中,m为0或1; n为0; R 32,R 32,R 34,R 34,R 35,R 32, R< 36>,R< 37>,< 38>,R 39,R 40, R 41和R 42各自表示氢原子; X表示可以被取代的炔基,芳基等; R 1和R 2各自独立地表示氢原子,烷基,烷氧基等,或其盐或水合物。
-
9.
公开(公告)号:US06699870B2
公开(公告)日:2004-03-02
申请号:US10281194
申请日:2002-10-28
申请人: Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
发明人: Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
IPC分类号: A61K31502
CPC分类号: C07D231/12 , C07D233/56 , C07D237/28 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/14 , C07D417/04 , C07D417/14 , C07D451/06 , C07D471/08 , C07D491/04 , C07D491/08 , C07D491/10
摘要: The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.
摘要翻译: 本发明提供作为下式表示的勃起功能障碍治疗剂的酞嗪化合物,其药理学上可接受的盐或其水合物:其中R 1和R 2彼此相同或不同, 可以被卤素原子取代的C1〜C4烷基,可被卤素原子或氰基取代的C1〜C4烷氧基; X表示氰基,硝基,卤素原子,可被取代的羟基亚氨基或可被取代的杂芳基; Y表示可以被取代的杂芳基,可以被取代的芳基,可以被取代的炔基,烯基,烷基,任选取代的饱和或不饱和的4-至8-元胺环,环胺化合物是 单环化合物,双环化合物或螺环化合物; l为1〜3的整数, 条件是其中l为1或2,X为氰基,硝基或氯原子,R 1为氯原子,R 2为甲氧基,Y为5-或6 被羟基取代的胺基环被排除。
-
公开(公告)号:US20090270433A1
公开(公告)日:2009-10-29
申请号:US12234116
申请日:2008-09-19
申请人: Richard Clark , Atsushi Takemura , Nobuhisa Watanabe , Osamu Asano , Tadashi Nagakura , Kimlyo Tabata
发明人: Richard Clark , Atsushi Takemura , Nobuhisa Watanabe , Osamu Asano , Tadashi Nagakura , Kimlyo Tabata
IPC分类号: A61K31/506 , C07D413/14 , C07D405/14 , A61K31/427
CPC分类号: C07D417/14 , C07D209/44 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要: A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.]
摘要翻译: 由以下通式(1)表示的化合物或其盐具有丝氨酸蛋白酶抑制活性,对凝血因子VIIa特别优异的抑制活性。 该化合物或其盐可用作与血栓形成相关的疾病的治疗和/或预防剂。 [其中R 1表示氢,R 2表示任选取代的苯基等,R 3表示任选取代的C 6-10芳基等]
-
-
-
-
-
-
-
-
-